175 related articles for article (PubMed ID: 3044634)
1. The disposition of carboplatin in ovarian cancer patients.
Gaver RC; Colombo N; Green MD; George AM; Deeb G; Morris AD; Canetta RM; Speyer JL; Farmen RH; Muggia FM
Cancer Chemother Pharmacol; 1988; 22(3):263-70. PubMed ID: 3044634
[TBL] [Abstract][Full Text] [Related]
2. The disposition of carboplatin in the beagle dog.
Gaver RC; George AM; Duncan GF; Morris AD; Deeb G; Faulkner HC; Farmen RH
Cancer Chemother Pharmacol; 1988; 21(3):197-202. PubMed ID: 3282707
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of carboplatin.
Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.
Mulder PO; de Vries EG; Uges DR; Scaf AH; Sleijfer DT; Mulder NH
Br J Cancer; 1990 Mar; 61(3):460-4. PubMed ID: 2183874
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of carboplatin after intraperitoneal administration.
Elferink F; van der Vijgh WJ; Klein I; ten Bokkel Huinink WW; Dubbelman R; McVie JG
Cancer Chemother Pharmacol; 1988; 21(1):57-60. PubMed ID: 3277734
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
Elferink F; van der Vijgh WJ; ten Bokkel Huinink WW; Vermorken JB; Klein I; Winograd B; Knobf MK; Simonetti G; Gall HE; McVie JG
Br J Cancer; 1987 Oct; 56(4):479-83. PubMed ID: 3689665
[TBL] [Abstract][Full Text] [Related]
11. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of zeniplatin in humans.
DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
14. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Newell DR; Siddik ZH; Gumbrell LA; Boxall FE; Gore ME; Smith IE; Calvert AH
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1399-405. PubMed ID: 3315699
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of platinum in cancer patients treated with carboplatin in combination with high-dose methotrexate.
el-Yazigi A; Amer M; Martin CR
Pharm Res; 1989 Jun; 6(6):492-6. PubMed ID: 2668915
[TBL] [Abstract][Full Text] [Related]
16. Comparative intraperitoneal pharmacokinetics of three platinum analogues.
Lind MJ; Murphy DJ; Sharma H; Tinker N; Smith A; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1991; 28(4):315-7. PubMed ID: 1879050
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
Ota K; Oguma T; Shimamura K
Anticancer Res; 1994; 14(3B):1383-7. PubMed ID: 8067710
[TBL] [Abstract][Full Text] [Related]
18. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group.
DeGregorio MW; Lum BL; Holleran WM; Wilbur BJ; Sikic BI
Cancer Chemother Pharmacol; 1986; 18(3):235-8. PubMed ID: 3542268
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Figg WD; Christian MC; Lush R; Link CJ; Davis P; Kohn E; Sarosy G; Rothenberg ML; Weiss RB; Ryan N; Jacobs J; Reed E
Biopharm Drug Dispos; 1997 May; 18(4):347-59. PubMed ID: 9158882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]